Healthcare News

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant...

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026  Balance sheet strengthened to fund operations...

Innovation still rules, but ownership of the entire supply-chain pipeline is becoming the next biggest strategic advantage in today’s markets.

Rapid progress from announcement of successful launch in under two weeks signals NewGen’s expertise and commitment Launch represents fulfilment of NewGen’s goals to spearhead Real World Asset...

MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and...

DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that...

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present a poster on its lead candidate,...

February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX...

Cannara completes C$6.3M non-brokered private placement at C$2.10/share with Phoenician; minor share sale by CEO Zohar Krivorot; AGM items approved.